Immunotherapy

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

Precigen will begin immediate promotion following FDA acceptance of Phase II data showing a 51% one-year surgery-free response under a favorable safety profile.